Open AccessOutcome in Children With Standard-Risk B-Cell Acute Lymphoblastic Leukemia: Results of Children’s Oncology Group Trial AALL0331
Author(s) -
Kelly W. Maloney,
Meenakshi Devidas,
Cindy Wang,
Leonard A. Mattano,
Alison M. Friedmann,
Patrick J. Buckley,
Michael J. Borowitz,
Andrew J. Carroll,
Julie M. GastierFoster,
Nyla A. Heerema,
Nina S. KadanLottick,
Mig L. Loh,
Yousif Matloub,
David T. Marshall,
Linda C. Stork,
Elizabeth A. Raetz,
Brent L. Wood,
Stephen P. Hunger,
William L. Carroll,
Naomi J. Winick
Publication year - 2020
Publication title -
journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.482
H-Index - 548
eISSN - 1527-7755
pISSN - 0732-183X
DOI - 10.1200/jco.19.01086
Subject(s) - medicine , minimal residual disease , vincristine , regimen , lymphoblastic leukemia , gastroenterology , leukemia , chemotherapy , surgery , cyclophosphamide
Children's Oncology Group (COG) AALL0331 tested whether intensified postinduction therapy that improves survival in children with high-risk B-cell acute lymphoblastic leukemia (ALL) would also improve outcomes for those with standard-risk (SR) ALL.